EUCTR2006-003387-55-GB进行中（未招募）1 期
A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerability of CDB-2914 with Levonorgestrel as Emergency Contraception Within 120 Hours Unprotected Intercourse ” (Phase III). - CDB-2914 vs LNG for EC
aboratoire HRA Pharma0 个研究点目标入组 2,044 人开始时间: 2008年2月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,044
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Aged 16 years or more;
- •- Menstruating women with regular menstrual cycle between 24 and 35 days and intra-individual variations less than 5 days;
- •- Request emergency contraception within 120 hours after unprotected intercourse as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure;
- •- No current use of hormonal contraception and having had at least one complete menstrual cycle (2 menses) since having stopped hormonal contraception;
- •- For women with a recent history of Depo Provera use, the most recent injection must have been at least 9 months before study entry and followed by at least one complete menstrual cycle (2 menses);
- •- Willing to not use hormonal methods of contraception until study completion;
- •- At least one complete menstrual cycle (2 menses) post miscarriage, delivery or abortion;
- •- For women who present more than 72 hours after intercourse, decline the insertion of an IUD for emergency contraception and/or have contraindications to IUD insertion;
- •- Able to provide Informed Consent in English;
- •- Give voluntary, written informed consent, and agree to observe all study requirements (the subject needs to be available for follow-up over the next 6 weeks).
- •-Willing to abstain from further acts of unprotected intercourse during participation in the study and until pregnancy status has been ascertained.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- One or more acts of unprotected intercourse more than 120 hours before requesting emergency contraception in the current cycle;
- •- Currently pregnant as confirmed by positive HSUP test performed at screening (Treatment Visit);
- •- Currently breast-feeding;
- •- Current use of hormonal contraception;
- •- Use of hormonal emergency contraception since last menstrual period;
- •- Current use of IUD;
- •- Tubal ligation;
- •- Partner with a vasectomy;
- •- Unsure about the date of the last menstrual period;
- •- Severe asthma insufficiently controlled by oral glucocorticoid;
- •- Currently enrolled in any other trial of investigational medicine
- •- hypersensitivity to the active substance levonorgestrel or any of the excipients of the drug products used in the study.
研究者
相似试验
招募中
3 期
A study to determine the effectiveness of BP16 (Denosumab)for treatment of Osteoporosis.CTRI/2023/11/059935CuraTeQ Biologics Private Ltd.
招募中
3 期
A study to evaluate the effect of BP11 (Omalizumab)for treatment of moderate to severe asthma.CTRI/2023/10/059224CuraTeQ Biologics Private Limited
招募中
3 期
A study to evaluate the efficacy, safety and immunogenicity of Bevacizumab in metastatic colorectal cancer patients.CTRI/2024/04/066032CuraTeQ Biologics Private Ltd
进行中（未招募）
不适用
A Safety and Tolerability Study of Doripenem Compared with Meropenem in Children Hospitalized with Complicated Intra-abdominal InfectionsComplicated Intra-Abdominal InfectionsMedDRA version: 14.0Level: LLTClassification code 10056570Term: Intra-abdominal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-015864-32-LVJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium140
进行中（未招募）
1 期
未命名试验EUCTR2012-002862-11-ATCubist Pharmaceuticals LLC, an indirect wholly-owned subsidiary of Merck Sharp & Dohme Corp.726